Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)
Keros Therapeutics (KROS) reported Change in Account Payables of -$697000.0 for Q4 2025, down 137.88% on a YoY basis from $1.8 million in Q4 2024, and up 76.41% quarter-over-quarter from -$3.0 million in Q3 2025.
Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025) Analysis & Trends
Keros Therapeutics has reported Change in Account Payables for 7 years, with the latest figure at -$697000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables fell 137.88% year-over-year to -$697000.0; the trailing twelve-month figure through Dec 2025 stood at -$3.0 million (down 1105.22% YoY), and the FY2025 full-year result was -$3.0 million, down 1105.22% from the prior year.
- Change in Account Payables for Q4 2025 stood at -$697000.0, up from -$3.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $4.7 million in Q2 2022, with the low at -$5.0 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$27950.0 across 5 years, with a median of -$79500.0 in 2023.
- Annual changes were most pronounced in 2024 — Change in Account Payables sank 774.73% — and 2025, when it jumped 8678.26%.
- Keros Therapeutics' Change in Account Payables stood at $823000.0 in 2021, then retreated by 27.7% to $595000.0 in 2022, then jumped by 75.46% to $1.0 million in 2023, then plunged by 128.07% to -$293000.0 in 2024, then tumbled by 137.88% to -$697000.0 in 2025.
- The last three Change in Account Payables figures came in at -$697000.0 (Q4 2025), -$3.0 million (Q3 2025), and -$1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | -697,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -697,000.00 |
| Dec 31, 2025 | -697,000.00 |
| Sep 30, 2025 | -2.96 Mn |
| Sep 30, 2025 | -2.96 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Jun 30, 2025 | -1.37 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | -293,000.00 |
| Dec 31, 2024 | -293,000.00 |
| Sep 30, 2024 | -1.59 Mn |
| Sep 30, 2024 | -1.59 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 23,000.00 |
| Mar 31, 2024 | 23,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | -182,000.00 |
| Sep 30, 2023 | -182,000.00 |